Spotlight On... Pfizer expanding API plant in Australia; Sun recalls tablets made at troubled Halol plant; Baxter recalls more saline solution; and more...

Pfizer ($PFE) will invest about $15.7 million (AU$21 million) to expand a plant in Adelaide, Australia, to increase the capacity of the active ingredient for Neulasta. No new jobs, however, are associated with the expansion, ABC in Australia reports. Site director Tony Mulcahy told the news service that the Adelaide facility makes the intermediate for pegfilgrastim, which is sent to a Pfizer plant in Croatia that does the fill-finish work. Story

> Sun Pharmaceutical is recalling 381,120 cartons of alendronate sodium tablets--manufactured at its troubled Halol plant in India--that failed impurity trials at the three-month testing period. Report

> Baxter ($BAX) is recalling another lot, 257,364 bottles, of saline solution after receiving another complaint that a container contained an insect. Report

> A registered nurse in Florida has been sentenced to three years in prison and must forfeit more than $310,000 after pleading guilty to four charges related to selling narcotics over an illegal internet pharmacy site that grossed $9 million in three years. Release

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.